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Abstract
Introduction: Currently only limited data exist regarding the availability and clinical use of molecular and immunological
tests for tuberculosis (TB) in the European setting.
Methods: Web-based survey of Paediatric-Tuberculosis-Network-European-Trialsgroup (ptbnet) and Tuberculosis-Network-
European-Trialsgroup (TBnet) members conducted June to December 2013. Both networks comprise clinicians,
microbiologists, epidemiologists and researchers predominately based in Europe.
Results: 191 healthcare professionals from 31 European countries participated. Overall, 26.8% of respondents did not have
access to the Xpert MTB/RIF assay; only 44.6% had access to the assay in-house. However, a substantial proportion had
access to other commercial and/or non-commercial PCR-based assays for TB (68.8% and 31.8%, respectively). Only 6.4% did
not have access to any PCR-based assays for TB. A large proportion of participants with access to the Xpert MTB/RIF assay
had used it for the analysis of non-respiratory samples [pleural fluid: 36.5%, gastric aspirates: 34.7%, cerebrospinal fluid:
34.7%, stool samples: 4.3%, blood/serum: 2.6%, ‘other samples’ (which included biopsy/tissue samples, lymph node
aspirates, joint aspirates and urine samples): 16.5%]. Regarding interferon-gamma release assays, a greater proportion of
respondents had access to the QuantiFERON-TB Gold assay (84.7%) than to the T-SPOT.TB assay (52.2%).
Conclusions: Both immunological and molecular TB tests are widely available across Europe. The QuantiFERON-TB Gold
assay is more widely used than the T-SPOT.TB assay, which may reflect the difficulties of integrating an ELISPOT assay into
the routine laboratory setting. Although Xpert MTB/RIF assays are optimised and solely licensed for the analysis of sputum
samples, in clinical practice they are commonly used for non-respiratory samples. Further research is needed to establish
how current molecular TB tests impact on patient care and outcome in the routine clinical setting.
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Introduction
Detection of Mycobacterium tuberculosis by microbiological meth-
ods remains the gold standard for the diagnosis of tuberculosis
(TB) disease in humans, also referred to as active TB. However,
traditional solid and liquid culture methods can take several weeks
to produce a positive result [1,2]. In recent years, several
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commercial molecular assays for the detection of M. tuberculosis,
based on the polymerase chain reaction (PCR) principle, have
become available, which have the advantage of potentially
significantly shortening the time needed to confirm suspected
TB disease [1,3–9].
In December 2010 the World Health Organization (WHO)
issued their official endorsement of the Xpert MTB/RIF assay
(Cepheid; Sunnyvale, CA, U.S.) for the diagnosis of TB [10]. The
assay is based on a qualitative, nested real-time PCR, which allows
the detection of M. tuberculosis complex in clinical samples, and
simultaneously detects mutations in the rpoB gene, which are
associated with rifampicin resistance [1,4,11,12].
To facilitate uptake and implementation of the Xpert MTB/
RIF assay globally, concessional pricing was negotiated for more
than 140 low- and middle-income countries. According to the
WHO, as of September 2013 a total of 1,843 GeneXpert
instruments and more than 4.2 million Xpert MTB/RIF
cartridges have been procured by 95 countries eligible for
concessional pricing [13]. However, while the WHO collects
and regularly publishes data on the progress of the global Xpert
MTB/RIF roll-out, this exclusively comprises data from countries
eligible for concessional pricing, which excludes all Western, and
the majority of Northern and Southern European countries.
Therefore, only very limited data regarding the availability and
clinical use of Xpert MTB/RIF assays and other molecular assays
in the European setting are currently available.
Interferon-gamma release assays (IGRA) were licensed for
clinical use in 2001 [14]. IGRA are solely licensed for the diagnosis
of latent TB infection, and rely on the detection of interferon-
gamma produced by sensitised T cells in response to stimulation
with M. tuberculosis-specific antigens [15–20]. Currently two IGRA
are commercially available, the QuantiFERON-TB Gold assay
(Cellestis/Qiagen; Carnegie, Australia) and the T-SPOT.TB assay
(Oxford Immunotech; Abingdon, United Kingdom), which are
based on ELISA and ELISPOT formats, respectively [17]. To
date, there are few data on the availability of IGRA across Europe,
since the WHO does not routinely collect data related to these
immunoassays.
The aims of this study were to determine the availability of
molecular microbiological and immunological diagnostic tests for
TB in European countries, to establish how these tests are being
used in clinical practice, and to determine how molecular tests are
currently being funded across Europe.
Methods
Participants
A web-based survey was conducted among the members of the
Paediatric Tuberculosis Network European Trialsgroup (ptbnet)
and the Tuberculosis Network European Trialsgroup (TBnet) over
a 6-month-period (June to December 2013). Both networks
comprise clinicians, microbiologists, epidemiologists and research-
ers, with the majority (86%; n= 545) of the members being based
in Europe (for further details see: http://www.tb-net.org/index.
php/about-us; http://www.tb-net.org/index.php/about-us/
tbnet-members; http://www.tb-net.org/index.php/ptbnet) [21].
Network members were contacted by email and invited to
complete the survey online.
Definitions
For the purpose of this study ‘Europe’ was defined according to
the United Nations Statistics Division definition, which currently
includes 42 countries (for further details see: http://unstats.un.
org/unsd/methods/m49/m49regin.htm#europe). ‘Eastern Eu-
rope’ was defined as a geographical region comprising the
following countries: Albania, Belarus, Bosnia and Herzegovina,
Bulgaria, Croatia, the Czech Republic, Estonia, Hungary, Latvia,
Lithuania, Macedonia, Moldova, Montenegro, Poland, Romania,
the Russian Federation, Serbia, Slovakia, Slovenia and Ukraine.
Survey instrument
The online survey instrument was developed and initially
trialled individually by all authors to identify potential technical
issues. Following this, the survey instrument was trialled by five
ptbnet members based in different European countries who were
not part of the study team. No technical issues were identified at
this stage, but minor adjustments were made to the question
wording based on the feedback provided. Table S1 (supplemen-
tary digital contents) provides a summary of the final survey
instrument.
Statistical analysis and data deposition
STATA (Version 12; StataCorp; College Station, TX, US) and
Prism (Version 5.0; GraphPad; La Jolla, CA, US) were used for
data analyses and construction of the figures. Fisher’s exact tests
were used to assess differences between subgroups of participants.
P-values,0.05 were considered to be statistically significant. The
original data are accessible via the University of Southampton
ePrints digital repository (at http://eprints.soton.ac.uk/364424/;
DOI: 10.5258/SOTON/364424).
Ethics approval
According to current UK National Research Ethics Service
(NRES) regulations, Research Ethics Committee review is not
required for research involving healthcare staff recruited as
research participants by virtue of their professional role (Gover-
nance Arrangements for Research Ethics Committees, paragraph
2.3.13). Participation in the survey was voluntary. No identifying/
personal information was collected. Participants were aware that
they were participating in research, and that the results would be
published.
Results
A total of 191 healthcare professionals from 31 European
countries (Austria, Belarus, Belgium, Bulgaria, Croatia, the Czech
Republic, Denmark, Finland, France, Germany, Greece, Hun-
gary, Italy, Lithuania, Macedonia, Moldova, the Netherlands,
Norway, Poland, Portugal, Romania, the Russian Federation,
Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey,
Ukraine, United Kingdom) participated in the survey, which
included 49 participants from Eastern Europe. This equates to a
response rate of 35.0%. Of the respondents, 65.6% classified
themselves as ‘senior doctors’ (consultant or above), 24.2% as
‘junior/middle grade doctors’, and 10.2% as ‘other profession’
(mainly comprising microbiologists, molecular biologists, public
health professionals, and researchers). Of the respondents, 32.7%
stated that they were exclusively managing children with TB,
34.5% exclusively adults with TB, and 32.7% both children and
adults. The majority of participants stated that they were working
in a university hospital or a regional hospital (58.3% and 20.0%,
respectively); few were working in a private practice or primary
care setting (0.6% and 4.4%, respectively). A small proportion of
participants stated that they were primarily working in a
laboratory setting or a public health institution (6.3% and 3.1%,
respectively). Participants stated the following specialties to be their
main area of work: general paediatrics (3.2%), paediatric
pulmonology (12.3%), paediatric infectious diseases (17.6%),
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general adult/internal medicine (1.6%), adult pulmonology
(25.7%), adult infectious diseases (14.4%), microbiology (17.1%),
general practice (0.5%); 7.5% of respondents chose ‘other’ (mainly
comprising public health, TB laboratories, and research). The
majority of participants stated that TB accounted for a large
proportion of their average workload [10–25% of their workload
(22.2%); 25–50% (12.5%); 50–75% (13.6%); 75–100% (26.7%)].
The majority of respondents stated that they had 20 or more
patients with active TB under their care per year on average [5–20
patients (28.7%); 20–50 (21.6%); .50 (29.3%)].
Figure 1 summarises the participants’ access to a range of
microbiological and immunological tests for TB. The vast majority
of respondents stated that they had access to both solid and liquid
mycobacterial cultures (91.1% and 95.5%, respectively). More
than a quarter (26.8%) stated that they did not have access to the
Xpert MTB/RIF assay; fewer than half (44.6%) stated that they
had access to this assay with the assay being performed at their
own institution. Among respondents exclusively providing care for
adults, 62.3% stated that they had access to the Xpert MTB/RIF
assay (performed at their own institution or as send-away test),
while 32.1% stated that they had no access. Among respondents
exclusively providing care for children and adolescents, 70.4%
stated that they had access to the Xpert MTB/RIF assay, while
24.1% stated that they had no access. There was no statistically
significant difference between these two subgroups regarding
access to the Xpert MTB/RIF assay (p = 0.39). Among the
subgroup of respondents based at a University hospital, 66.7%
stated that they had access to the Xpert MTB/RIF assay, while
32.4% stated that they had no access. Among the subgroup of
respondents based at a regional hospital or in primary care, 73.7%
stated that they had access to the Xpert MTB/RIF assay, while
23.7% stated that they had no access. There was no statistically
significant difference between these two subgroups regarding
access to the Xpert MTB/RIF assay (p = 0.40). Among the
University-based subgroup with access to the Xpert MTB/RIF
assay, 62.9% stated the assay was performed at their own
institution, while 37.1% stated the assay was performed elsewhere
(send-away test); among the regional hospital- and primary care-
based subgroup with access to the Xpert MTB/RIF assay, 60.7%
stated the assay was performed at their own institution, while
39.3% stated the assay was performed elsewhere (p = 1.00).
Overall, a substantial proportion of respondents stated that they
had access to other commercial and/or non-commercial PCR-
based assays for TB (68.8% and 31.8%, respectively; see Figure 1
for details regarding ‘other commercial assays’). Only 6.4% of
respondents stated that they did not have access to any PCR-based
assays for TB; the majority of those respondents were based in
Eastern European countries (Bulgaria, Romania, and Ukraine).
Fewer respondents stated that they had access (either performed at
the same institution or as send-away test) to the T-SPOT.TB
compared with the QuantiFERON-TB Gold assay (52.2% versus
84.7%).
Figure 2 summarises the participants’ responses regarding their
ability to access the Xpert MTB/RIF assay according to country.
In most countries one or more of the respondents had access to the
assay in-house. All respondents from Belgium (n = 5), Lithuania
(n = 1), Portugal (n = 2), Romania (n = 7), Serbia (n = 1), and
Slovenia (n = 2) stated that they did not have access to the assay in-
house; however one or more respondent(s) from those countries
stated that they had access to the assay as send-away test, showing
that the assay is available at least on a national level. All
respondents from the Czech Republic (n = 3) and all respondents
from Denmark (n = 5) stated that did not have access to the Xpert
MTB/RIF assay, either in-house or as send-away test; however, all
Czech and four of the five Danish respondents indicated that they
had access to another commercial PCR-based test for TB.
Among participants who had access to the Xpert MTB/RIF
assay (n = 109), the majority (95.2%) stated that they had used this
assay for the analysis of respiratory samples, 36.5% for pleural
fluid, 34.7% for gastric aspirates, 34.7% for cerebrospinal fluid
(CSF) samples, 4.3% for stool samples, and 2.6% for blood or
serum. In addition, 16.5% stated that they had used the assay for
the analysis of ‘other samples’, which included biopsy/tissue
samples, lymph node aspirates, joint aspirates and urine samples.
The participants who stated that they had used the assay for the
analysis of ‘other samples’ (n = 18) were based in a variety of
European countries (Belarus, Belgium, Croatia, Finland, France,
Italy, the Russian Federation, Slovenia, Spain, Switzerland,
Turkey, United Kingdom), with the majority being based at
regional or university hospitals (n = 5 and n= 12, respectively).
When asked whether they had ever started a patient on
treatment for drug-resistant TB based on history/clinical features
and then changed back to treatment for drug-susceptible TB based
on an Xpert MTB/RIF assay result suggesting that the organism
was susceptible (ie rather than awaiting the results of phenotypic
testing), the majority (68.2%) of respondents with access to these
assays answered ‘no, never’; a further 19.6% answered ‘yes, but
only rarely’. There was no statistically significant difference
between Eastern European participants and participants from
other parts of Europe (65.6% vs. 69.3% chose ‘no, never’,
respectively; p = 0.82). There was also no statistically significant
difference between participants based at a University hospital and
those based at a regional hospital or in primary care (68.3% vs.
65.4% chose ‘no, never’, respectively; p = 0.81). When asked
whether they had ever started a patient on treatment for drug-
resistant TB based on an Xpert MTB/RIF assay result suggesting
that the organism was resistant (ie rather than awaiting the results
of phenotypic testing), 36.9% of respondents with access to these
assays answered ‘no, never’, 25.2% ‘yes, but only rarely’, and
30.1% ‘yes, regularly’. There was no statistically significant
difference between Eastern European participants and participants
from other parts of Europe (36.3% vs. 27.1% chose ‘yes, regularly’,
respectively; p = 0.10). There was also no statistically significant
difference between participants based at a University hospital and
those based at a regional hospital or in primary care (26.2% vs.
42.3% chose ‘yes, regularly’, respectively; p = 0.20).
With regards to funding of the Xpert MTB/RIF or an
alternative molecular TB test, respondents most commonly stated
that the costs were covered by national insurance/national
healthcare cover (37.7%), followed by the hospital (22.6%) and
the patient’s health insurance (21.8%); a smaller proportion
(10.9%) indicated that the costs were covered by a public health
service (eg TB control program); none of the participants indicated
that the patient himself/herself had to cover the costs.
Discussion
To our knowledge this is the first study to assess the current
landscape of immunological and molecular microbiological assays
for the diagnosis of TB across Europe. A number of interesting
conclusions can be drawn from the results of this survey. Firstly, in
the European setting access to conventional microbiological
culture methods and IGRA is widespread. Interestingly, a far
greater proportion of survey participants had access to the
QuantiFERON-TB Gold assay compared with the T-SPOT.TB
assay, which may reflect the greater difficulties of integrating an
ELISPOT assay into the routine diagnostic laboratory setting.
Molecular and Immunological TB Tests in Europe
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Figure 1. Summary of participants’ responses regarding their access to immunological, conventional microbiological and
molecular tests for tuberculosis.
doi:10.1371/journal.pone.0099129.g001
Figure 2. Summary of participants’ responses regarding their access to the Xpert MTB/RIF assay according to country.
doi:10.1371/journal.pone.0099129.g002
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The majority of participants had access to molecular TB tests.
Interestingly, our results show that University hospital-based
physicians were no more likely to have access to the Xpert
MTB/RIF assay than their colleagues based in the primary care
or regional hospital setting. Although a quarter of the participants
did not have access to the Xpert MTB/RIF assay, the results show
that a large proportion of participants had access to a range of
other commercial and non-commercial PCR-based tests. Further-
more, the results show that the Xpert MTB/RIF assay was
available to healthcare professionals providing care for patients
with TB in most European countries, albeit in some only at
regional or supra-regional level (ie as send-away test). This aspect
is important, as emerging data suggest that centralised placement
of the analytical instrument (eg in a reference laboratory at
regional level) may be considerably less useful for patient
management than use of the assay in a near-patient setting (ie
point-of-care test in a TB outpatient clinic), as the former can
extend the time required to produce a test result significantly
(potentially until after management decisions have already been
made), and poses additional challenges regarding linkage of results
[11,22].
Interestingly, a large proportion of participants had used the
Xpert MTB/RIF assay for the analysis of a variety of non-
respiratory samples, despite the fact that the assay has been
optimised and is solely licensed for the analysis of sputum samples
[23]. Importantly, while there are data suggesting that the
sensitivity of the Xpert MTB/RIF assay is relatively high with
CSF and biopsy samples, previous reports have shown the
performance to be suboptimal with stool samples, and pleural,
peritoneal and joint fluids [24-32]. Notably, the recent WHO
policy update on the use of the Xpert MTB/RIF assay for the
diagnosis of pulmonary and extrapulmonary TB recommends that
the assay should be used in preference to conventional microscopy
and culture as initial diagnostic test for CSF specimens in patients
presumed to have TB meningitis [33]. In addition, the policy
update also recommends the use of this assay as a replacement test
for usual practice (including microscopy, culture, and/or histopa-
thology) for testing of lymph node and other tissues in patients
presumed to have extrapulmonary TB. However, the document
also states that both recommendations are based on very low
quality evidence, and highlights that these recommendations do
not apply to other biological samples (including stool, urine and
blood).
Surprisingly, a large proportion of participants who had access
to the Xpert MTB/RIF assay indicated that they were not using
the resistance result of the test for clinical management decisions
on a regular basis. However, it is difficult to draw firm conclusions
from this, as the utility of the Xpert MTB/RIF resistance result
depends on the prevalence of rifampicin resistance in the
population the test is being applied to (ie greater positive predictive
value in populations with high proportions of multidrug-resistant
(MDR)-TB). However, our data indicate that participants from
Eastern European countries, where the rates of MDR-TB are
generally higher than in other European countries [34,35], are no
more likely to base management decisions regularly on the PCR-
based resistance result than their colleagues from other parts of
Europe. This highlights that further studies are needed to
determine how current molecular TB tests impact on patient care
and outcome in a routine clinical setting in Europe, particularly in
view of a recent study from South Africa that has highlighted the
limited impact of the Xpert MTB/RIF assay on management
decisions, and ultimately patient outcomes [36].
Limitations
The response rate in this survey was suboptimal. However, a
response rate of 35.0% is considered to be average to good in the
context of online surveys [37]. The survey was conducted among
healthcare professionals and researchers who are part of a
dedicated TB network and have a particular interest and/or
expertise in the area of TB, and the data may therefore not be fully
representative of the situation in a respective country. Notably, the
majority of respondents were working in a tertiary care setting,
where the availability of diagnostic tests for TB is likely to be
greater than at the primary or secondary care level. Therefore, the
results may overestimate the availability of the tests in Eastern
European countries, where many TB patients are receiving care
outside the tertiary care setting. However, in countries with low
TB prevalence the majority of suspected and confirmed cases of
active TB are receiving care at tertiary level, supporting the
validity of the survey findings particularly in relation to Western
and Northern European countries. It is possible that healthcare
professionals with particularly high workloads were less likely to
participate in this survey, which may have introduced a bias. For
some countries the number of survey participants was compara-
tively small, and some of the data may therefore not be
representative of the country as a whole. Nevertheless, the data
show that while molecular assays may not be available to some
individual healthcare professionals, they are available at least at
regional or supra-regional level in most European countries.
Conclusions
Both immunological and molecular microbiological tests for the
diagnosis of TB are widely available across Europe. The
QuantiFERON-TB Gold assay is more widely used than the T-
SPOT.TB assay. The Xpert MTB/RIF assay is available to
healthcare professionals in most European countries; the majority
of healthcare professionals providing care for TB patients who do
not have access to this assay have access to other molecular tests
for TB. In clinical practice the Xpert MTB/RIF assay is
commonly used for the analysis of non-respiratory samples,
despite the fact that the assay is optimised for the analysis of
sputum samples. A large proportion of healthcare professionals
indicated that they were not using the resistance result of the Xpert
MTB/RIF assay for clinical management decisions on a regular
basis. Therefore, further research is needed to establish how
current molecular TB tests impact on patient care and outcome in
a routine clinical setting.
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